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CtBPs (CtBP1 and CtBP2) act in the nucleus as transcriptional corepressors and in the cytoplasm as regulators
of Golgi apparatus fission. Studies in which the expression or function of CtBPs has been inhibited have indepen-
dently identified roles for CtBPs in both suppressing apoptosis and promoting cell cycle progression. Here, we have
analyzed the consequences of ablating CtBP expression in breast cancer-derived cell lines. We found that loss of
CtBP expression suppresses cell proliferation through a combination of apoptosis, reduction in cell cycle progres-
sion, and aberrations in transit through mitosis. The third phenotype includes errors in mitotic chromosome
segregation that are associated with decreased association of the chromosome passenger protein aurora B with
mitotic chromatin and that are likely to be a primary cause of the proapoptotic and antiproliferative effects of CtBP
loss. We also show that loss of CtBP expression results in the activation of the transcription factor p53 and that loss
of p53 function renders cells more susceptible to CtBP small interfering RNA-induced apoptosis.
Chromosome segregation during mitosis involves the bipolar
(amphitelic) attachment of paired sister chromatids to micro-
tubules of the mitotic spindle, equal distribution of the repli-
cated chromosomes, and finally cytokinesis. The spindle as-
sembly checkpoint (SAC) is a key determinant of the fidelity of
chromosome segregation; it can be viewed as an “anaphase
wait signal,” holding cells in metaphase until all criteria for
equal chromosome segregation are met (25, 30, 38). SAC pro-
teins accumulate at kinetochores of unattached chromosomes,
providing a signal that maintains inhibition of the anaphase-
promoting complex until bipolar attachments have been made
and the SAC proteins are displaced from the kinetochores.
Many aspects of mitosis are regulated by a complex of chro-
mosomal passenger proteins, notably aurora B kinase and its
regulators survivin, borealin, and INCENP (38, 43, 55). Inhib-
iting the expression and/or activity of chromosomal passenger
proteins results in severe mitotic defects (17, 20, 32). Cell
death may occur as a consequence of such defects, and thus,
proteins such as survivin and aurora B kinase are currently
under intense investigation as targets for anticancer therapeu-
tics (13, 61).
CtBPs (C-terminal binding proteins) were originally identi-
fied as cellular binding partners of type 2/5 adenovirus 243R
E1A proteins (4). What are now known to be consensus CtBP-
binding motifs, PXDLS, were subsequently identified within
the C termini of E1A and EBNA3C (45, 52, 54). Deletion of
these regions from either of these two proteins markedly alters
their ability to transform cells in cooperation with mutant
RAS, providing compelling evidence for a key role of CtBPs in
cellular transformation (4, 45). Recent studies have provided
more direct evidence; CtBPs form functional interactions with
multiple cellular proteins that have diverse roles in intracellu-
lar signaling and transcriptional control (1, 5, 6, 54), experi-
mental suppression of CtBP expression renders cancer cells
hypersensitive to apoptosis (19, 37, 63), and the cytotoxic ef-
fects of certain genotoxic cancer chemotherapeutics can be, in
part, due to the activation of signaling pathways that promote
CtBP degradation (58).
In mammals, CtBPs are expressed from two genes, CTBP1
and CTBP2. Human and rodent CTBP1 genes are expressed as
two main splice forms, CtBP1-L and CtBP1-S, which differ by
13 amino acids at their N termini (5). Murine Ctbp2 undergoes
similar alternative splicing (56). Human CtBP1-L and CtBP2-L
are highly similar proteins of 440 and 445 amino acids, respec-
tively. They are widely expressed in normal tissues. CtBPs are
characterized by a conserved central NADH-dependent dimer-
ization domain. Their N- and C-terminal regions form a single
globular domain, which binds PXDLS-containing proteins
(35). CtBPs can function interchangeably in many assays; there
are, however, differences in their regulation, particularly at the
level of their subcellular distribution; notably, only CtBP2-L
contains a nuclear localization/retention sequence, located at
its unique N terminus (2, 56, 64).
CtBPs have been ascribed two distinct functions; in the nu-
cleus, they act as transcriptional corepressors (1, 5, 6, 54),
whereas in the cytoplasm, they are involved in the fission of
Golgi and endocytic membranes (3, 5, 11). Mechanistically, as
corepressors, CtBPs primarily function as a scaffold to recruit
chromatin-modifying enzymes, including histone deacetylases
(HDACs), histone methyltransferases, and polycomb group
proteins, to DNA-binding transcription factors (26, 47). Of the
many CtBP-recruiting transcription factors, the best character-
ized include SLUG and ZEB/EF1, which repress the expres-
sion of epithelium-specific genes (15, 19, 41, 47, 53). In the
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Golgi apparatus, membrane fission has been reported to be
dependent upon a CtBP1-S-associated lipid-specific acyl-trans-
ferase activity (11), though the nature of this activity is unclear
(16).
The diverse functions of CtBP proteins in the nucleus and
cytoplasm are reflected in studies in which the phenotypic
consequences of genetic or functional ablation of CtBPs have
been investigated. Disruption of dCtBP in Drosophila results in
embryonic segmentation defects consistent with aberrant tran-
scriptional control (36, 40). Similarly, Ctbp1//Ctbp2/ mice
die early in development, with their embryonic fibroblasts dis-
playing abnormal transcription and hypersensitivity to apop-
tosis signals but a normal Golgi apparatus architecture (19,
23). The hypersensitivity to apoptosis is associated with an
upregulation in the expression of multiple proapoptotic genes
through an as yet undetermined p53-independent pathway
(19). RNA interference (RNAi)-mediated depletion of CtBPs
in various cancer cell lines is also, on its own, sufficient to
induce p53-independent apoptosis (37, 63). CtBP-dependent
transcriptional regulation also plays an important role in the
control of tumor cell migration (62). In apparent contrast,
studies focusing upon the role of CtBPs in Golgi membrane
fission have demonstrated that the ablation of CtBP function
or expression can result in a “Golgi checkpoint” in G2, pre-
venting entry into mitosis (10, 22). To clarify our understand-
ing of the role of CtBPs in the proliferation and survival of
cancer cells, we performed a detailed analysis of the pheno-
typic consequences of inhibiting CtBP expression in breast
cancer-derived cell lines. These studies have revealed a previ-
ously unidentified role of CtBPs in the regulation of mitotic
fidelity and the SAC that is an important component of the
prosurvival activity of these proteins.
MATERIALS AND METHODS
Statistical analysis. Unless otherwise stated, error bars on graphs represent
the standard error of the mean of three independent experiments. The statistical
significance of differences was determined using paired two-tailed Student’s t
tests (Microsoft Excel) comparing CtBP small interfering RNA (siRNA)- to
control siRNA-transfected cells, unless otherwise indicated. P values of less than
0.05 are marked with one asterisk, and those less than 0.02 are marked with two
asterisks.
Cell culture and RNAi. All cells were maintained in Dulbecco’s modified Eagle
medium (Invitrogen) supplemented with 10% fetal bovine serum (Autogen Bio-
clear) and penicillin (100 U/ml), streptomycin (100 g/ml), and L-glutamine (292
g/ml) (Invitrogen). RNAi-mediated CtBP knockdown was performed using the
siRNA 5-GGGAGGACCUGGAGAAGUUdTdT-3/3-dTdTCCCUCCUGGAC
CUCUUCAA-5, obtained from Ambion. CtBP1 siRNA (5-ACGACUUCACCG
UCAAGCAdTdT-3/3-dTdTUGCUGAAGUGGCAGUUCGU-5), CtBP 2 siRNA
(5-GCGCCUUGGUCAGUAAUAGdTdT-3/3-dTdTCGCGGAACCAGUCAUU
AUC-5), p53 siRNA (Hs_TP53_9 HP Validated; catalog no.S102655170) and aurora B
siRNA (target, AAGGTGATGGAGAATAGCAGT) were obtained from Qiagen.
Negative control siRNA no. 1 (Ambion) was used for experimental controls. siRNA
was transfected using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. The growth medium was replaced 4 h after transfection and,
unless otherwise stated, was not replaced before the assay. To make RNAi-insensi-
tive plasmids for rescue experiments, plasmids pcDNA3.1CtBP2(1-445)mh (34) and
pcDNA3.1CtBP1(1-440)mh (2) were modified by site-directed mutagenesis (Quick-
change; Stratagene) to make synonymous changes in the RNAi target sequence (mh
stands for myc-His tag). The sequence of the forward mutagenesis primer for CtBP1
was 5-CACCATCACTCTCACGCGTGAAGATTTAGAAAAATTCAAAGCCC
TCCGC-3, and for CtBP2 it was 5-ACCATCACCCTCACGCGTGAAGATTTA
GAAAAATTCAAGGCCCTGAGA-3. Caspase inhibitor Q-VD-OPH (QVD)
was from Calbiochem.
Cell proliferation and viability assays and live-cell imaging. For cell prolifer-
ation assays, adherent cells in wells of 24-well plates were detached using trypsin
and counted using a hemocytometer. For colony-forming assays, cells were de-
tached with trypsin 2 days posttransfection in 96-well plates and replated into
6-well plates. The cells were grown for a further 10 to 12 days with a change of
growth medium every 3 to 4 days. Colonies were stained with Giemsa (Sigma)
and counted manually. Fluorescence time-lapse microscopy on H2B-GFP (green
fluorescent protein) HeLa cells was carried out using a Zeiss Live Cell Observer
with a 37°C incubator and a 5% CO2 hood. Images were captured every 15 min
using a 20 objective on a Zeiss AxioCam MRm camera with AxioVision
software. Time lapse microscopy of MCF-7 cells was performed using an Olym-
pus IX81 microscope with a CO2- and temperature-controlled environmental
chamber controlled by SIS Cell P software. Image J software was used for
analysis.
Flow cytometry. For determination of DNA content, all floating and attached
cells were collected and combined for analysis. Ethanol-fixed cell samples were
washed with phosphate-buffered saline (PBS) and stained in freshly prepared
propidium iodide buffer (20 g/ml propidium iodide, 0.2 mg/ml RNase A, 0.1%
[vol/vol] Triton X-100 in PBS) for 30 min at room temperature. Flow cytometry
was performed using a FACSCalibur (Becton Dickinson) equipped with
CellQuest software (Becton Dickinson).
Antibodies and immunoblotting. The following antibodies were used: mouse
monoclonal antibodies against CtBP1 (E12; Santa Cruz Biotechnologies), CtBP2
(E16 [Santa Cruz Biotechnologies] or clone 16 [Becton Dickinson]), anti-
p21WAF1 (OP64; Calbiochem), CENP-A and six-His (ab13939, and ab9108;
AbCam), AIM-1 (aurora B) (611082; BD Biosciences), p53 (clone DO-1; Sero-
tec), phosphohistone H3 (Ser10) (clone 3H10; Upstate), and rabbit polyclonal
against actin (20-33; Sigma). Antibody E12, which was raised against human
CtBP1, is marketed as recognizing both CtBP1 and CtBP2; however, it does not
recognize recombinant human CtBP2 (see Fig. S6 in the supplemental material;
data not shown) and can be used to selectively detect CtBP1 in humans. For
immunoblotting, adherent cells were washed with PBS, scraped into PBS, and
pelleted by centrifugation. Cell lysis was performed for 15 min at 4°C in 2
volumes of urea lysis buffer (7 M urea, 0.05% Triton X-100, 25 mM NaCl, 20 mM
HEPES, pH 7.6, 100 mM dithiothreitol). Lysates were clarified by centrifugation
at 13,000  g for 10 min. Protein was quantified using Bio-Rad protein assay
reagent. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to Hybond-ECL membranes (GE Healthcare).
Blocking and antibody incubations were done in 3% low-fat milk in PBS–0.025%
Tween 20, and washes were in PBS–0.1% Tween 20. Detection of horseradish
peroxidase-labeled secondary antibody was done with Supersignal (Pierce), and
images were collected and analyzed on a Fluor-S MultiImager (Bio-Rad)
equipped with Quantity One software (Bio-Rad).
Immunofluorescence analysis, mitotic index, and micronucleus counts. Cells
growing on 13-mm glass coverslips were fixed with 4% paraformaldehyde in PBS
for 10 min. For immunofluorescence assays, cells were permeabilized using 0.1%
Triton X-100/PBS for 20 min, blocked for 30 min in 3% bovine serum albumin/
PBS, and incubated with primary antibody for 1 h in 0.6% bovine serum albumin/
PBS, followed by species-specific secondary antibody. The secondary antibodies
were as follows: Alexa Fluor 594-conjugated anti-mouse immunoglobulin G
(Molecular Probes), fluorescein isothiocyanate- or tetramethyl rhodamine isothio-
cyanate-conjugated anti-rabbit immunoglobulins, and tetramethyl rhodamine iso-
thiocyanate-conjugated anti-mouse immunoglobulins (DakoCytomation). Cells
were counterstained with 1 g/ml DAPI (4,6-diamidino-2-phenylindole) during
the secondary-antibody incubation. Coverslips were mounted on slides with
fluorescent mounting medium (DakoCytomation). All cells were visualized using
a Zeiss Axiovert 200 fluorescence microscope with a 40 or 100 objective, and
images were collected using an Orca-ER digital camera (Hamamatsu) and pro-
cessed using Openlab 3.5.1 Software (Improvision). Identical exposure times
were applied for different images within the same experiment. Images were
cropped using Corel Photo-Paint 12. Aurora B fluorescence was quantified using
Openlab 3.5.1 software and was normalized to the DNA content as assessed by
DAPI staining. The mitotic index was determined by counting 500 cells per
slide and scoring the cells as either mitotic or interphase according to the state
of chromosome condensation. For micronucleus analysis, 200 cells per slide
were analyzed.
RESULTS
Inhibition of CtBP synthesis inhibits breast cancer cell pro-
liferation. To investigate the role of CtBPs in the proliferation
of breast cancer cells, we used an siRNA to target a sequence
conserved in known human CtBP1- and CtBP2-encoding
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mRNAs (63). In referring to experiments using this reagent,
we have therefore used the terms “CtBP” and “CtBPs” to refer
to both family members and denote individual proteins when
appropriate. We first transfected MCF-7 cells with CtBP-spe-
cific or control siRNA, harvested cells at 24-h intervals post-
transfection, and determined the abundances of CtBP1 and
CtBP2 proteins (Fig. 1A [days 1 to 4 shown]). CtBP siRNA
downregulated CtBP expression within 24 h, with maximum
effect at days 2 to 5. CtBP1 was depleted by up to 85% and
CtBP2 to below the limits of detection. By day 7, CtBP protein
abundance had begun to recover (not shown). In MDA-MB-
231 and ZR75.1 cells, CtBP siRNA similarly reduced CtBP
abundance (Fig. 1A). Expression of both CtBP1 and CtBP2
was reduced in up to 95% of the cells (see Fig. S1 in the
supplemental material).
We next established the effects of inhibiting CtBP synthesis
FIG. 1. Downregulation of CtBP protein expression in breast cancer cell lines by RNAi. (A) Immunoblots showing CtBP1 and CtBP2 proteins
compared to actin loading control (42 kDa) at the indicated times following transfection. Lanes: a, nontransfected; b, control siRNA; c, CtBP
siRNA. (B) Colony-forming assays 12 to 14 days posttransfection. Solid bars, control siRNA; open bars, CtBP siRNA (MCF-7, n  9;
MDA-MB-231, n  9; ZR75.1, n  6). (C) Cells were plated at 5  104 (MCF-7) or 7  104 (MDA-MB-231) cells per well 1 day prior to
transfection (note that plating efficiency was 100%). The numbers of adherent cells at the indicated time points following transfection with
control (solid symbols) or CtBP (open symbols) siRNA are shown. Triangles, MCF-7 cells; diamonds, MDA-MB-231 cells. The data represent
means of two duplicate dishes. (D) Time lapse microscopy of MCF-7 and MDA-MB-231 cells following siRNA-mediated inhibition of CtBP
expression 2.5 to 3.5 days posttransfection (see Videos S1 to S4 in the supplemental material). (Di) Change in total cell numbers in the imaged
fields over 24 h. (Dii) Number of mitotic events observed. (Dii) Number of cell deaths observed. Solid bars, control siRNA; open bars, CtBP siRNA
(MCF-7, n  5 fields; MDA-MB-231, n  5 fields.) The data are representative of two independent experiments for each cell line.
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on the ability of single breast cancer cells to establish colonies
when plated 2 days posttransfection with siRNA (Fig. 1B).
CtBP siRNA resulted in significant decreases in the number of
colonies relative to control siRNA-transfected cells (2-fold,
6-fold, and 36-fold for ZR75.1, MCF-7, and MDA-MB-231
cells, respectively). We also determined the total numbers of
adherent MCF-7 and MDA-MB-231 cells following their trans-
fection with siRNA (Fig. 1C). The numbers of CtBP-depleted
cells were lower than those of control cells by 2 days posttrans-
fection and were at their lowest (and more than fourfold less
than control transfectants) at day 4, after which cell numbers
began to increase. Similar results were obtained with ZR75.1
cells (data not shown). To determine whether this was due to
effects on cell division or cell death, we performed live-cell
imaging analysis. Cells were imaged for 24 h over the period
from 2.5 to 3.5 days posttransfection (see Videos S1 to S4 in
the supplemental material). Whereas the numbers of control
siRNA-transfected MCF-7 and MDA-MB-231 cells increased
during this period by 49% and 29%, respectively, following
CtBP siRNA there was a significant decrease in both MCF-7
cells (9%) and MDA-MB-231 cells (37%) (Fig. 1Di). These
data are consistent with those obtained by cell counting (Fig.
1C). CtBP siRNA caused a significant (eight- to ninefold)
decrease in the number of mitotic events in this period (Fig.
1Dii). The rate of cell death was also increased, from 1.8 to 9.7
deaths per 100 cells in MCF-7 and from 1.7 to 35.7 deaths per
100 cells in MDA-MB-231 (Fig. 1Diii). The greater effect of
CtBP siRNA on cell death in MDA-MB-231 cells would ac-
count for the much larger decrease in cell population over that
seen with MCF-7 cells during this period. Together, these data
clearly establish that loss of CtBP expression results in a
marked reduction in the proliferative capacity of breast cancer
cells.
Loss of CtBP results in increased apoptosis and reduced cell
division. To determine whether the cell death induced by CtBP
siRNA is apoptosis, we determined whether this death was
inhibited by the caspase inhibitor QVD (Fig. 2A; see Videos S5
and S6 in the supplemental material). As previously shown,
CtBP depletion induces cell death in both MCF-7 and MDA-
MB-231 cells. However, in the presence of QVD, deaths over
the 10-h period of analysis were significantly reduced, from
7.8/100 to 0.5/100 in MCF-7 cells and from 24.2/100 to 1.2/100
in MDA-MB-231 cells (Fig. 2Aii). This effect was reflected in
the total change in cell numbers during the imaging period
(Fig. 2Ai) (QVD treatment had no effect on the number of
mitoses [not shown]). Therefore, inhibition of CtBP expression
results in a marked induction of apoptosis in MDA-MB-231
cells, with a more modest increase occurring in MCF-7 cells.
Live-cell imaging also demonstrated that CtBP ablation re-
sulted in reduced mitosis of breast cancer cells. We therefore
counted the mitotic index of cells 4 days posttransfection with
siRNA (Fig. 2B). Compared to control siRNA transfection,
CtBP siRNA resulted in a significant (P 0.05) four- to sixfold
reduction in the mitotic index in all three cell lines examined.
FIG. 2. Analysis of apoptosis and cell proliferation in CtBP-depleted cells. (A) Time lapse microscopy of MCF-7 and MDA-MB-231 from 2.5
days posttransfection with the indicated siRNA. Where indicated, 25 M QVD was added 4 h prior to the start of time lapse analysis (see Videos
S5 and S6 in the supplemental material). (Ai) Change in total cell numbers over 10 h. (Aii) Number of cell deaths observed. Solid bars, no QVD;
open bars, 25 M QVD (MCF-7, n  5; MDA-MB-231, n  5). (B) Cells were fixed for analysis of the mitotic index 4 days posttransfection with
control (solid bars) or CtBP (open bars) siRNA. (Ci) Analysis of MCF-7 cells in late G2, as indicated by speckled phosphohistone H3 staining.
More than 500 cells were scored per slide. (Cii) Immunofluorescence staining of phosphohistone H3 expression in MCF-7 cells 4 days posttrans-
fection. The arrows indicate cells in late G2. Bar, 10 m. Color images, including staining of a mitotic nucleus for comparison, are shown in Fig.
S2 in the supplemental material.
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We therefore examined whether this was due to arrest of
CtBP-depleted cells in G2 by examining histone H3 phosphor-
ylation (Fig. 2C). During late G2, histone H3 is phosphorylated
primarily in pericentromeric heterochromatin, giving a very
distinct speckled staining pattern, which allows the identifica-
tion of cells in late G2 (21). When a “Golgi checkpoint” is
activated by inhibition of CtBP expression or function, cells
accumulate in late G2 and can be detected by this assay (22).
There was a significant (P  0.02) decrease in the number of
MCF-7 cells compared to control cells in late G2 after CtBP
siRNA. Therefore, the reduced entry into mitosis seen in
CtBP-depleted breast cancer cells is not due to a late G2 arrest,
but rather, must be due to fewer cells entering G2, or possibly
successfully traversing this cell cycle phase.
Loss of CtBP leads to multiple mitotic defects. To investi-
gate whether breast cancer cells arrest at a specific point of the
cell cycle after CtBP siRNA, we performed flow cytometry
analysis of DNA content (Fig. 3A). This analysis did not reveal
any striking single effect of the CtBP siRNA that alone might
account for its effect on cell proliferation. Consistent with
induction of apoptosis, there was a modest increase in the
number of events with a sub-G1 DNA content in CtBP-de-
pleted MCF-7 and MDA-MB-231 cells at both 2 and 4 days
posttransfection (not shown). There was also a modest but
consistent increase in the proportion of cells with 4N DNA
content in both cell lines at 2 and 4 days posttransfection. This
is generally indicative of accumulation in G2 or M phase.
However, we have already shown that there is a decrease in
cells in M and late G2 phases after CtBP depletion. An alter-
native cause of an increase of 4N cells is failures in mitosis that
result in the generation of binucleate cells. At day 4 posttrans-
fection, MDA-MB-231 cells also consistently showed a small
increase in the 2N to 4N (usually S phase) fraction; this was not
observed in MCF-7 cells.
We then further analyzed the phenotype of CtBP-depleted
cells by detailed morphological analysis of DAPI-stained cell
nuclei. In addition to the previously described reduction in the
mitotic index (Fig. 2B), we identified multiple morphological
defects consistent with aberrant transit through mitosis. First,
there was a significant increase in the occurrence of binucleate
cells, from 2.0% of the total population in controls to 6.2%,
following CtBP siRNA transfection. This suggests that a pro-
portion of the cells undergo cell division without segregating
their DNA and is consistent with the modest increase in cells
with 4N DNA content seen with flow cytometry. Furthermore,
in all three cell lines examined, CtBP siRNA caused a three- to
fourfold increase in the proportion of the cells containing
micronuclei (Fig. 3Bii to iv) (a similar result was obtained in
nontransformed human fibroblasts [see Fig. S7 in the supple-
mental material], indicating that this response is not restricted
to cancer cell lines). Analysis of the alignment and segregation
of condensed chromosomes in mitosis also revealed that CtBP
siRNA resulted in increased numbers of cells containing lag-
ging chromosomes and chromatin bridges (Fig. 3C and D). For
example, 26.7% 	 5.3% of control siRNA-transfected MCF-7
cells undergoing anaphase exhibited lagging chromosomes
compared to 55.5%	 6.7% following CtBP siRNA (P 0.02).
Micronuclei can arise from whole chromosomes that lag at
mitosis due to, for example, a damaged kinetochore or faulty
spindle apparatus or from acentric chromosome fragments cre-
ated by DNA breaks. It was thus important to determine
whether the micronuclei found in CtBP-depleted cells were
derived from whole chromosomes or chromosome fragments.
To do this, we assessed the presence of the kinetochore protein
CENP-A in the micronuclei (see Fig. S3 in the supplemental
material). CENP-A was detected in 60 to 70% of micronuclei
in both control and CtBP siRNA-transfected cells (Fig. 3E). As
a control, we used ionizing radiation to cause DNA breaks, as

85% of radiation-induced micronuclei arise from acentric
chromosome fragments (57). Less than 20% of the micronuclei
formed in irradiated MCF-7 cells stained positive for CENP-A.
Therefore micronuclei seen in CtBP-depleted cells contain
whole chromosomes as opposed to chromosome fragments,
and these are probably formed from the lagging chromosomes
observed during mitosis.
Known functions of CtBPs provide little clue as to why their
depletion might result in these abnormalities in mitosis; one
possibility, given the role of CtBPs in Golgi apparatus fission
during G2 phase, is that it is a result of cells entering mitosis
with an incorrectly organized Golgi apparatus. Normal rat
kidney cells injected with a CtBP-inhibiting antibody or trans-
fected with antisense CtBP siRNA primarily arrest in late G2;
however, the cells that do enter mitosis following CtBP anti-
body injection are clearly characterized by the presence of
aggregated Golgi complexes (22). We therefore determined
the structure of the Golgi apparatus during mitosis in siRNA-
transfected MCF-7 cells by immunolocalization of golgin 97.
Particular attention was paid to cells in metaphase, as this is
the stage of mitosis in which fragmentation of the Golgi
apparatus is most apparent. Compared to control siRNA-
transfected cells, there was no observable difference in the
phenotype of the Golgi apparatus during mitosis in CtBP
siRNA-transfected cells (see Fig. S4 in the supplemental
material). It is possible that these cells had only escaped a
Golgi-dependent G2 checkpoint and entered mitosis as a con-
sequence of insufficient knockdown of the CtBP. However,
chromosome segregation defects were clearly observable in
CtBP siRNA-transfected cells that had normal mitotic Golgi
apparatus fragmentation (see Fig. S4 in the supplemental ma-
terial), and we therefore consider it highly unlikely that these
defects were a consequence of a loss of CtBP-dependent Golgi
apparatus fission.
Reduction in mitotic fidelity by CtBP siRNA is due to on-
target effects. As loss of mitotic fidelity has not been reported
following other methods of CtBP ablation, we next used the
two independent approaches of rescue and redundancy (14) to
establish that this was not due to off-target effects of the CtBP
siRNA. In each approach, we scored the occurrence of micro-
nuclei as a marker of mitotic abnormalities. Figure 4A, B, and
C show that the effects of the CtBP siRNA on micronucleus
formation were replicated when a combination of two inde-
pendent siRNAs to CtBP1 and CtBP2 were cotransfected (Fig.
4C). For a rescue approach, we transfected CtBP1 or CtBP2
protein expression plasmids containing synonymous mutations
in the CtBP siRNA target sequence together with the siRNA
(Fig. 4D). While this experimental approach resulted in an
overall increase in the numbers of cells containing micronuclei
in control siRNA-transfected cells, an effect which we believe
to be either a consequence of cellular stress following plasmid
DNA transfection or formation of micronuclei directly from
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cytoplasmic plasmid DNA (31), when cotransfected with the
control LacZ plasmid, CtBP siRNA still caused a significant
increase in micronucleus-containing cells. In contrast, when
cotransfected with either siRNA-insensitive CtBP1 or CtBP2
expression vectors, CtBP siRNA had no effect on micronucleus
formation. Together, these two independent approaches con-
firm that CtBP siRNA induces the formation of micronuclei
through specific on-target effects.
Evidence that CtBPs promote mitotic fidelity through effects
on the cellular activity of chromosome passenger proteins. To
further define the nature of the mitotic abnormalities that
follow inhibition of CtBP synthesis, we used live-cell imaging
to assess transit through mitosis. We initially analyzed HeLa
cells stably expressing GFP-histone H2B, in order to permit
visualization of chromatin during mitosis. CtBP siRNA re-
sulted in a striking increase in the mean length of time a cell
FIG. 3. Evidence of chromosome segregation defects following loss of CtBP. (A) Graph showing DNA content as assessed by flow cytometry
analysis of the indicated cell lines transfected with the indicated siRNA and analyzed 2 to 4 days later. The data are representative of at least three
separate experiments. Fragments with sub-2N DNA content were excluded from the analysis. Con, control. (B) Mitotic phenotypes 4 days
posttransfection with control (solid bars) or CtBP (open bars) siRNA. (Bi) Percentages of MCF-7 cells with binuclear and multinuclear phenotypes
4 days after transfection with control or CtBP siRNA. (Bii) Quantification of micronucleus occurrence. (Biii and Biv) DAPI-stained MCF-7 nuclei
of control-siRNA (Biii)- and CtBP siRNA (Biv)-transfected cells 4 days posttransfection. Micronuclei are indicated by arrows. Bar, 10 m. Of the
three cell lines included in this study, MCF-7 cells possess the best combination of morphology and transfection efficiency for detailed cellular
analyses. (C) MCF-7 cells at different stages of mitosis 3 days posttransfection with control (i, ii, and iii) or CtBP (iv, v, and vi) siRNA. Lagging
chromosomes and chromatin bridges are indicated by arrows. Bar, 10 m. (D) Quantification of mitotic defects in MCF-7 cells 3 days
posttransfection with control (solid bars) or CtBP (open bars) siRNA. More than 25 events were scored per stage of mitosis per slide.
(E) Quantification of immunofluorescence analysis of CENP-A in MCF-7 cells 4 days posttransfection with no siRNA, control siRNA, or CtBP
siRNA or 2 days postexposure to 5 Gy ionizing radiation. More than 30 micronuclei were scored per slide as staining either positive or negative
for CENP-A.
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spent in mitosis (Fig. 5A and B; see Videos S7 and S8 in the
supplemental material). This delay was primarily a conse-
quence of cells spending a longer time in prometaphase, which
can indicate prolonged activation of the SAC. Additionally,
25% of the cells that did enter mitosis ultimately failed to
complete cytokinesis, resulting in the generation of a binucle-
ate cell (Fig. 5A and C). Specifically, these cells commence
cytokinesis and successfully form a cleavage furrow; however,
this subsequently regresses, and no abscission occurs; the cells
rejoin shortly afterward (Fig. 5A). CtBP siRNA had very sim-
ilar effects on MCF-7 cells, with a significant extension of the
time spent in mitosis, and an increase in the proportion of
mitoses that ended in failed cytokinesis (Fig. 5D and E). To-
gether with the analysis of fixed cells, these results indicate that
loss of CtBPs results in chromosome alignment defects and
activation of the SAC. We have confirmed that the SAC is
indeed activated in these cells by determining that the SAC
protein BubR1 is recruited to kinetochores (see Fig. S8 in the
supplemental material). However, this checkpoint is ultimately
not sustained, and cells initiate anaphase with errors in chro-
mosome segregation and either fail in cytokinesis or divide to
form aberrant daughter cells.
Causes of the abnormalities in chromosome alignment in
metaphase could include either gross abnormalities in assem-
bly of the spindle or failure of the normal mechanism of spin-
dle connection to kinetochores and chromosome orientation.
We have excluded gross microtubule spindle abnormalities, as
immunodetection of - and -tubulin in CtBP-depleted
MCF-7 cells revealed no observable defects in the morphology
of the microtubule spindle or centrosome numbers (see Fig. S5
in the supplemental material; data not shown). The defects in
chromosome segregation and cytokinesis following CtBP si-
lencing are similar to those seen following inhibition of the
activity of aurora B kinase (20, 46, 49) or expression of its
regulator, survivin (29). We therefore examined whether au-
rora B expression and/or localization were abnormal in CtBP-
depleted cells. Western blot analysis (Fig. 5F) showed that
aurora B is reduced to an undetectable level in MCF-7 cells
transfected with either CtBP-specific siRNA or the combina-
tion of CtBP1 and CtBP2-specific siRNAs. As aurora B ex-
pression is cell cycle regulated (24), this reduction could be due
to the reduced number of cells in mitosis. We therefore used
immunofluorescence to visualize and quantify aurora B in mi-
totic cells. During mitosis, aurora B first localizes to centro-
meres in prophase and remains concentrated at centromeres
until it relocalizes to the central spindle at the start of an-
FIG. 4. CtBP siRNA induces chromosome segregation defects through on-target effects. (A) Immunoblots showing CtBP1 and CtBP2
depletion in MCF-7 and MDA-MB-231 cells using either CtBP siRNA or CtBP1 and CtBP2 siRNAs individually or in combination (total siRNA
concentration, 100 nM) 3 days posttransfection. Actin (42 kDa) was included as a loading control. (B) MCF-7 cells were fixed for analysis of the
mitotic index 3 days posttransfection with control, CtBP, or CtBP1 plus CtBP2 siRNA. Analysis of variance (ANOVA) was used for statistical
analysis. (C) Quantification of micronuclei in MCF-7 cells 3 days posttransfection with control, CtBP, or CtBP1 plus CtBP2 siRNA. ANOVA was
used for statistical analysis. (D) MCF-7 cells were cotransfected with control (solid bars) or CtBP (open bars) siRNA and plasmids encoding
His-tagged RNAi-insensitive CtBP proteins or His-tagged -galactosidase control (lacZ). The cells were immunostained with anti-six-His antibody,
and the percentage of His fusion protein-expressing cells that contained micronuclei was determined at day 4 posttransfection.
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FIG. 5. Analysis of the effects of CtBP siRNA on progression through mitosis. (A, B, and C) HeLa cells stably expressing GFP-histone H2B
were transfected with either control or CtBP siRNA and analyzed by time lapse microscopy 24 h later (see Videos S7 and S8 in the supplemental
material). (A) Representative time lapse images of individual cells undergoing mitosis. (B) Time taken for cells to complete mitosis. The bars
through clusters of time points represent the mean times taken to complete mitosis. Similar results were obtained in an independent experiment.
(C) Percentage of cells that displayed defects in cytokinesis. Similar results were obtained in an independent experiment. (D) Time taken for
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aphase, where it subsequently concentrates at the midbody
(51). Compared to control cells, CtBP-siRNA-treated cells
showed a 2-fold reduction (P  0.01) in the accumulation of
aurora B on chromatin in prophase and prometaphase cells
(Fig. 5Gi and Gii). Aurora B subsequently localized to the
midbody in anaphase in both control and CtBP siRNA-treated
cells; we were unable to reliably quantify its abundance within
these structures. We have discovered, therefore, that CtBPs
have a novel function in regulating the association of the chro-
mosome passenger protein aurora B with chromatin in early
mitosis. Based on what is known of the functions of aurora B,
compromising this association would be expected to result in
phenotypic abnormalities in mitosis of the type that occurs in
CtBP-depleted cells. To confirm this, we used siRNA to reduce
aurora B expression in MCF-7 cells and found the expected
increase in the frequency of cells containing micronuclei
(Fig. 5H).
p53 protects breast cancer cells from CtBP siRNA-induced
apoptosis. It was important to determine whether this novel
role of CtBPs in the regulation of mitotic fidelity plays a role in
its prosurvival activity. We therefore examined whether cells
that had exited mitosis with incorrectly segregated chromo-
somes showed an increased propensity to undergo apoptosis.
Figure 6A shows that when cells are prevented from undergo-
ing apoptosis with the caspase inhibitor QVD, the proportion
of cells in the population that contain micronuclei increases.
This accumulation was seen in both MCF-7 and MDA-MB-231
cells with or without the transfection of CtBP siRNA. Inter-
estingly, whereas in CtBP siRNA-transfected MDA-MB-231
cells QVD markedly increased the proportion of the popula-
tion containing micronuclei from 22.5% 	 0.5% to 32.4% 	
0.7%, this accumulation was much less in CtBP siRNA-trans-
fected MCF-7 cells. Thus, the increased rates of apoptosis
in response to CtBP siRNA in MDA-MB-231 compared to
MCF-7 cells can be accounted for, at least in part, by apoptosis
in cells that have failed to accurately segregate their chromo-
somes in mitosis.
Cells that exit mitosis with incorrectly segregated DNA can
undergo a postmitotic G1 arrest that prevents replication of
aberrant cells (27). This checkpoint can be an important de-
terminant of cellular viability in such cells, notably when chro-
mosome segregation defects have been induced by the inhibi-
tion of aurora kinases (18). Given that p53 mutation status is
one of the known molecular differences between MCF-7 (wild-
type) and MDA-MB-231 (R280K-inactivating mutant) cells,
we assessed the role of p53 in the cellular response to CtBP
siRNA. In MCF-7 cells, CtBP siRNA resulted in a 10-fold
upregulation of the p53 protein 3 days posttransfection (Fig.
6B), consistent with p53 activation. A similar p53 response to
CtBP knockdown was found in a nontransformed human fi-
broblast cell line (see Fig. S7 in the supplemental material).
We therefore cotransfected cells with siRNAs for both CtBP
and p53 (Fig. 6E); again, CtBP siRNA induced an increase in
p53 protein abundance, as well as upregulation of p21WAF1,
the transcription of which is induced by p53. p53 siRNA sup-
pressed the CtBP siRNA-induced increase in the abundance of
both p53 and p21WAF1 proteins. Twenty-four-hour live-cell
imaging analysis (Fig. 6D; see Videos S9 and S10 in the sup-
plemental material) showed that, whereas p53 siRNA alone
had no significant effect on MCF-7 cell numbers and CtBP
depletion resulted in a 10% decrease as shown previously,
when CtBP and p53 were depleted simultaneously, cell num-
bers were reduced by 35% (Fig. 6Di), a figure that is similar to
that seen after CtBP depletion in MDA-MB-231 cells (Fig.
1Di). This large reduction in cell numbers after combined
CtBP-p53 ablation was primarily a consequence of a large
increase in cell death to 40/100 cells (Fig. 6Dii). There was also
a further reduction in the mitotic index (Fig. 6Diii). These
effects of p53 on cell survival were also seen in long-term
clonogenic assays (Fig. 6E) and were confirmed using a second
siRNA to p53 (see Fig. S9 in the supplemental material).
Together, these data demonstrate that loss of CtBP expression
in wild-type p53-expressing cells results in the activation of a
p53 response. In the absence of this response, cells depleted of
CtBPs are prone to high rates of apoptotic cell death.
DISCUSSION
The aim of this study was to better define the mechanistic
basis of the prosurvival and proproliferative activities of CtBPs
(reviewed in references 1 and 6). We discovered that CtBPs
are required for the maintenance of mitotic fidelity. In addition
to being a previously unidentified cellular role for these pro-
teins, this is an important component of their prosurvival func-
tion. We also found, consistent with previous studies, that the
cell death that is induced by CtBP knockdown does not require
p53 function. However, in cells with functional p53, we found
that loss of CtBP does induce a cellular p53 response that
includes upregulation of the cyclin-dependent kinase inhibitor
p21WAF1. Furthermore, by suppressing the p53-independent
apoptotic response, p53 has a protective effect in CtBP-de-
pleted cells.
CtBP siRNA-treated cells display a marked reduction in the
number of cells that enter mitosis. Based on previous studies,
the failure of cells to enter mitosis was expected, due to a
demonstrated requirement for CtBPs for fissioning of the
Golgi apparatus prior to mitotic entry (10, 22). However in our
experiments, rather than activation of a “Golgi checkpoint” in
late G2, CtBP siRNA resulted in a reduction in the number of
cells in late G2 sufficient to account for the reduced mitotic
MCF-7 cells to complete mitosis 3 days posttransfection with either control (solid bars [see Video S1 in the supplemental material]) or CtBP (open
bars [see Video S2 in the supplemental material]) siRNA. The bars indicate means plus standard errors of the mean for60 mitoses. Results from
two independent experiments are shown. (E) Percentage of the mitoses analyzed in panel D that exhibited abnormal cytokinesis. (F) Immunoblot
showing aurora B in MCF-7 cells 3 days posttransfection with either control siRNA, CtBP siRNA (CtBP1/2), or both CtBP1 and CtBP2 siRNAs
(CtBP12). (Gi) Immunofluorescence staining of aurora B (red) in prometaphase MCF-7 cells 3 days posttransfection with either control or CtBP
siRNA. Bar, 10 m. (Gii) Quantification of aurora B immunofluorescence intensity (normalized to the DNA content as assessed by DAPI staining)
in prophase and prometaphase MCF-7 cells. The data are from a representative of three separate experiments in which 20 cells were scored per
slide. (H) MCF-7 cells were transfected with the indicated siRNA and assessed for the presence of micronuclei 3 days later.
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entry. This appears to be due to a cell line- and/or p53-depen-
dent combination of death and arrest, most likely predomi-
nantly in G1 and/or S phase. Presumably, the lack of a Golgi
apparatus phenotype in our experiments indicates that these
breast cancer cells express endophilin B or other such factors
that are now known to be interchangeable with CtBPs in Golgi
apparatus fission (60).
We found three distinct, though potentially interrelated, mi-
totic phenotypes in CtBP siRNA-treated cells: (i) lagging chro-
mosomes during mitosis and, in interphase cells, micronuclei
that contained primarily centromere-containing chromatin, to-
gether indicative of entry into anaphase prior to completion of
amphitelic attachment of paired sister chromatids to microtu-
bules; (ii) an extended average time spent in mitosis, with
mitosis being delayed predominantly at the prometaphase
stage; and (iii) failure of a proportion of cells to complete the
final, abscission, phase of cytokinesis, resulting in the genera-
tion of binucleate cell progeny. Given that all known delays in
mitosis are mediated by the SAC (42), it can be concluded
from the second phenotype that this checkpoint is activated for
longer in CtBP-compromised cells than in controls. Many con-
ditions are able to induce a delay in mitosis, including defects
in centrosome separation, anchorage of microtubules to kineto-
chores, formation of stable microtubule-kinetochore attach-
ments, prevention of cyclin B/CDK1 inactivation, or global
DNA damage (42). The combined mitotic phenotype of CtBP-
compromised cells most closely resembles a modest form of
that obtained when both the formation of stable microtubule
attachments and cytokinesis are disrupted through the exper-
imental targeting of chromosome passenger proteins, notably
FIG. 6. p53 protects breast cancer cells from CtBP siRNA-induced apoptosis. (A) Quantification of micronuclei in MCF-7 and MDA-MB-231
cells 3 days posttransfection with control or CtBP siRNA. Solid bars, no QVD; open bars, 25 M QVD added 24 h prior to fixing the cells.
(B) Immunoblot showing p53 protein abundance in MCF-7 cells 3 days posttransfection with CtBP siRNA compared to control siRNA.
(C) Immunoblot confirming effects of siRNAs on the abundance of their targets in MCF-7 cells. The abundance of the p53-induced protein
p21WAF1 was also examined. (D) Time lapse microscopy analysis of MCF-7 cells 2.5 to 3.5 days posttransfection with either control, p53, CtBP,
or CtBP plus p53 siRNA (n 5). The transfection conditions were the same as for panel C. (See Videos S9 and S10 in the supplemental material.)
(Di) Change in total cell numbers over 24 h. (Dii) Number of cell deaths observed. (Diii) Number of mitotic events observed. Analysis of variance
was used for statistical analysis. (E) Giemsa staining of MCF-7 cell colonies 10 days posttransfection with either control, CtBP, p53, or CtBP plus
p53 siRNA.
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aurora B kinase (12, 20, 46) and survivin (29). We therefore
examined the effects of CtBP knockdown on accumulation of
aurora B on mitotic chromosomes and found the accumulation
to be reduced.
Early in mitosis, SAC proteins localize to outer kinetochores
lacking attached microtubules and maintain the anaphase wait
signal until microtubule attachment leads to their release from
the kinetochore (30, 33). Kinetochore-microtubule attach-
ments that result in both sister chromatids being connected to
the same spindle pole (merotelic attachments) are thought to
be severed through a chromosome passenger protein-depen-
dent pathway, resulting in rerecruitment of SAC proteins and
ensuring the anaphase wait signal is maintained until all pairs
of sister chromatids have correct bipolar attachments (7, 38,
43). Reduced efficacy of this aurora B kinase-dependent pro-
cess would provide an explanation for the mitotic phenotypes
i and ii we observed in CtBP-depleted cells, i.e., the overall
process would take longer, resulting in a prolonged SAC and
extended time in mitosis (phenotype ii). However, when only a
small number of inappropriate connections are left, some may
theoretically remain undetected by chromosomal passenger
proteins for long enough for anaphase-promoting complex ac-
tivity to be derepressed and anaphase initiated. Such a mech-
anism would result in lagging chromosomes and the subse-
quent micronuclei that we observed (phenotype i). A recent
study in which cells were exposed to a low concentration of the
kinase inhibitor ZM447439 clearly demonstrated that the fre-
quency of formation of lagging chromosomes is very sensitive
to partial inhibition of aurora enzyme activity (9). Subsequent
to anaphase, chromosome passenger proteins migrate to the
central spindle and are required for cytokinesis, which fails if
their expression is compromised, producing binucleate cells
(12, 20, 29, 46, 55). Critically, aurora B activity is required for
the activation of an abscission checkpoint in response to chro-
matin being trapped within the cleavage furrow due to chro-
matin bridges. Loss of this activity results in a failure to resolve
the bridges, and the cleavage furrow regresses, resulting in the
formation of a tetraploid cell (49). Even partial inhibition of
aurora activity can cause a modest increase in the frequency of
failed cytokinesis (9), again comparable to the effects of CtBP
siRNA (phenotype iii).
At present, based on known functions of CtBPs, it is not
clear how they may exert their effects on aurora B, mitotic
progression, and mitotic fidelity. There are, however, a number
of important observations that provide avenues for investiga-
tion. Might CtBPs play a direct role in mitosis, or is the effect
indirect, for example, through regulating the transcription of
other genes with roles in mitosis? The latter is certainly pos-
sible, as FoxM1, a gene with a critical role in many aspects of
cell division, including mitotic entry, centrosome amplification,
and the spindle checkpoint (28), is upregulated in Ctbp1/
Ctbp2/ murine embryo fibroblasts (19). The reduced accumu-
lation of aurora B on prophase and prometaphase chromatin in
CtBP-depleted cells could be due to either effects on the overall
abundance of aurora B in mitotic cells or its recruitment to cen-
tromeres as a component of the chromosome passenger complex.
With respect to the latter, it is striking that treatment of cells in S
phase with pharmacological inhibitors of HDAC activity cause
delay in the subsequent mitosis, as well as defects in chromosome
alignment and increased frequency of lagging chromosomes, and
failed cytokinesis (8, 50, 59). A reduction in the concentration of
chromosomal passenger proteins, including aurora B, in prophase
and prometaphase centromeres, with no effect on the overall
abundance of these proteins in mitotic cells, appears to underlie
this phenotype (50), though further details of the mechanism
remain to be elucidated. Given that HDACs are a core compo-
nent of CtBP complexes in cells (26, 47), the mitotic phenotypes
of CtBP siRNA-treated cells could be a consequence of hyper-
acetylation of histones in S phase. Finally, in contrast, CtBPs may
have a direct role in mitosis; it has long been recognized that
CtBP1 is differentially phosphorylated through the cell cycle, with
overall phosphorylation reaching a peak during mitosis (4). In
addition CtBPs localize to centrosomes throughout mitosis in a
complex including -tubulin and Plk1 (48).
Several reports have clearly demonstrated that CtBPs play a
prosurvival role, with loss of their expression resulting in either
apoptosis or hypersensitivity to apoptotic stimuli through a
p53-independent mechanism (19, 37, 63; reviewed in refer-
ences 1 and 6). This is an important observation, because
CtBPs are also targeted for degradation in response to cancer
chemotherapeutic agents, such as cisplatin, a response that is
part of the cytotoxic mechanism of such agents (58). However,
the involvement of CtBPs in such a wide range of key intra-
cellular signaling pathways (1, 6) has made it difficult to define
the mechanistic basis of this prosurvival activity. Indeed, it
seems probable that CtBPs impinge upon more than one an-
tiapoptotic pathway; suppression of anoikis through the inhi-
bition of epithelial gene expression in cells with a mesenchymal
phenotype appears to be one such pathway (19); here, we show
the maintenance of mitotic fidelity to be another. Studies with
aurora kinase inhibitors (12, 18) have found that, in the ab-
sence of a functional p53 stress response pathway, cells that
exit mitosis following failed cytokinesis enter subsequent
rounds of S phase, in which they show a high propensity to
undergo cell death. We found that the inhibition of apoptosis
in the breast cancer cell lines led to an increase in the propor-
tion of cells that contained micronuclei. This effect was very
apparent in MDA-MB-231 cells in which CtBP expression had
been inhibited. Thus, in this mutant p53-expressing cell line,
cells that have undergone chromosome segregation defects in
response to CtBP siRNA show an increased propensity to
undergo subsequent apoptosis compared to cells without such
defects.
Inhibition of CtBP expression in the MCF-7 breast cancer
cell line caused a clear increase in p53 protein abundance and
upregulation of its transcriptional target, p21WAF1. By extra-
polation from previous studies in which the effects of chromo-
some segregation defects in wild-type p53-expressing cells were
examined (12, 18, 44), it seems likely that this p53 activation
occurs in G1 cells in response to the consequences of chromo-
some segregation defects in the prior mitosis. It is quite pos-
sible that loss of CtBP expression also leads to p53 activation
through additional pathways in these cells, particularly given
the previously described physical and functional interaction
between CtBPs and the p53 negative-regulatory partner
HDM2 (34). However, despite the mechanism of p53 induc-
tion, it is clear from our data that p53 protects MCF-7 cells
from loss of CtBP expression in short-term apoptosis assays
and also in longer-term tests of clonogenic survival. While p53
is generally considered to be a proapoptotic molecule, pre-
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vious studies have shown that p53-dependent expression of
p21WAF1, which induces cell cycle arrest primarily in G1 phase,
can protect cells from p53-dependent apoptosis (39). This
p21WAF1 induction can also protect from apoptosis in cells that
contain chromosome segregation defects as a consequence of
their exposure to aurora kinase inhibitors (18). It seems prob-
able that a similar response protects CtBP-depleted cells. The
ability to induce cell death with selectivity for cells with a
mutation in p53 would be a useful property in any cancer
chemotherapeutic drug. Our study therefore supports previous
assertions that CtBPs warrant further investigation for their
potential as targets for cancer therapeutics (58). It would also
be important to determine the extent to which the loss of
CtBP-dependent maintenance of mitotic fidelity plays a role in
the cellular response to other agents with anticaner activity,
notably genotoxics, such as cisplatin, and HDAC inhibitors.
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